Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
UPMC Hillman Cancer Center · University of Pennsylvania · +2 more institutions
Indexed incrossrefpubmed
Abstract
Background
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity.
Methods
.
Citation impact
85
total citations
- FWCI
- 66.75
- Percentile
- 100%
- References
- 39
Citations per year
Authors
34- JSJakub SvobodaCorresponding
UPMC Hillman Cancer Center, University of Pennsylvania
- DJDaniel J. Landsburg
UPMC Hillman Cancer Center, University of Pennsylvania
- JNJames N. Gerson
University of Vermont Medical Center
- SDSunita D. Nasta
UPMC Hillman Cancer Center, University of Pennsylvania
- SKStefan K. Barta
UPMC Hillman Cancer Center, University of Pennsylvania
Topics & keywords
Topics
Keywords
- Lymphoma
- CAR T-cell therapy
- Medicine
- Cancer research
- Oncology
- Internal medicine
- Immunotherapy
- Cancer
No related works found for this paper.